Diagnostic ultrasound ( PDFDrive )

CHAPTER 3 Contrast Agents for Ultrasound 73
in abdominal applications: retrospective analysis of 23188 investigations.
Ultrasound Med Biol. 2006;32(9):1369-1375.
93. Kaufman DW. Risk of anaphylaxis in a hospital population in relation to
the use of various drugs: an international study. Pharmacoepidemiol Drug
Saf. 2003;12(3):195-202.
94. Kusnetzky LL, Khalid A, Khumri TM, et al. Acute mortality in hospitalized
patients undergoing echocardiography with and without an ultrasound
contrast agent: results in 18,671 consecutive studies. J Am Coll Cardiol.
2008;51:1704-1706.
95. Main ML, Ryan AC, Davis TE, et al. Acute mortality in hospitalized patients
undergoing echocardiography with and without an ultrasound contrast
agent (multicenter registry results in 4,300,966 consecutive patients). Am
J Cardiol. 2008;102(12):1742-1746.
96. Main M. Ultrasound contrast agent safety: from anecdote to evidence.
JACC Cardiovasc Imaging. 2009;2(9):1057-1059.
97. US Food and Drug Administration (FDA). Micro-bubble Contrast Agents
(marketed as Deinity (Perlutren Lipid Microsphere) Injectable Suspension
and Optison (Perlutren Protein-Type Microspheres for Injection). 2008.
Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/
SafetyAlertsforHumanMedicalProducts/ucm092270.htm.
98. Health_Canada. Updated safety information on DEFINITY (Perlutren
Injectable Suspension). Available from: http://www.hc-sc.gc.ca/dhp-mps/
medeff/advisories-avis/prof/_2008/deinity_hpc-cps_2-eng.php.
99. Wilson SR, Burns PN. Microbubble-enhanced US in body imaging: what
role? Radiology. 2010;257(1):24-39.
100. Rychak JJ, Lindner JR, Ley K, Klibanov AL. Deformable gas-illed microbubbles
targeted to P-selectin. J Control Release. 2006;114(3):288-299.
101. Christiansen JP, Lindner JR. Molecular and cellular imaging with targeted
contrast ultrasound. Proc IEEE. 2005;93:809-818.
102. Klibanov AL, Rychak JJ, Yang WC, et al. Targeted ultrasound contrast agent
for molecular imaging of inlammation in high-shear low. Contrast Media
Mol Imaging. 2006;1(6):259-266.
103. Rychak JJ, Graba J, Cheung AM, et al. Microultrasound molecular imaging
of vascular endothelial growth factor receptor 2 in a mouse model of tumor
angiogenesis. Mol Imaging. 2007;6(5):289-296.
104. Behm CZ, Lindner JR. Cellular and molecular imaging with targeted contrast
ultrasound. Ultrasound Q. 2006;22(1):67-72.
105. Pochon S, Tardy I, Bussat P, et al. BR55: a lipopeptide-based VEGFR2-targeted
ultrasound contrast agent for molecular imaging of angiogenesis. Invest
Radiol. 2010;45(2):89-95.
106. Brooks JD, Gambhir SS, Lutz A, Wilmann JK. A pilot clinical trial using
BR55 ultrasound contrast agent in the assessment of prostate cancer by
molecular imaging of VEGFR2. Stanford University. 2016. Available from:
http://med.stanford.edu/clinicaltrials/trials/NCT02142608.
107. Liu Y, Miyoshi H, Nakamura M. Encapsulated ultrasound microbubbles:
therapeutic application in drug/gene delivery. J Control Release. 2006;114(1):
89-99.
108. Leong-Poi H, Kuliszewski MA, Lekas M, et al. herapeutic arteriogenesis
by ultrasound-mediated VEGF165 plasmid gene delivery to chronically
ischemic skeletal muscle. Circ Res. 2007;101(3):295-303.
109. Williams R, Wright C, Cherin E, et al. Characterization of submicron
phase-change perluorocarbon droplets for extravascular ultrasound imaging
of cancer. Ultrasound Med Biol. 2013;39(3):475-489.
110. Giesecke T, Hynynen K. Ultrasound-mediated cavitation thresholds of liquid
perluorocarbon droplets in vitro. Ultrasound Med Biol. 2003;29(9):
1359-1365.